Key Highlights
- First-quarter adjusted earnings reached $2.65 per share, surpassing Wall Street’s $2.59 projection
- Quarterly revenue totaled $15 billion, marking a 12% annual increase and exceeding the $14.72 billion consensus
- Immunology division expanded 16%, while neuroscience division surged 26% during the period
- Company elevated full-year 2026 adjusted EPS forecast to $14.08–$14.28 range, up from previous $13.96–$14.16 guidance
- Shares climbed 2.5% during premarket hours, clawing back portion of year-to-date 13% decline
AbbVie entered Wednesday’s quarterly report carrying a 13% year-to-date loss. Investors left with renewed optimism.
The biopharmaceutical giant delivered first-quarter adjusted profits of $2.65 per share, marking an improvement from $2.46 in the comparable 2025 period and surpassing the Street’s $2.59 estimate. Quarterly revenue reached $15 billion, representing a 12% year-over-year climb that exceeded analyst projections of $14.72 billion.
ABBV shares advanced 2.5% to $202.63 during premarket activity following the announcement.
The revenue outperformance stemmed primarily from strength across two strategic business segments. The immunology portfolio delivered 16% growth, while the neuroscience division produced an even more impressive 26% expansion.
Skyrizi and Rinvoq remained the primary growth drivers within immunology. Skyrizi, prescribed for arthritis and Crohn’s disease management, expanded revenue by 31% during the quarter. Rinvoq contributed with 23% growth momentum.
These robust performances helped counterbalance a steep 39% revenue decline from Humira. The former flagship product faces intensifying pressure from biosimilar alternatives, and its share within the overall product mix continues diminishing.
Management Elevates Annual Projections
AbbVie upgraded its full-year 2026 adjusted EPS projection to a $14.08–$14.28 range, representing an increase from the previously communicated $13.96–$14.16 outlook. The Street’s current consensus estimate stands at $14.12, positioning the revised midpoint modestly above analyst expectations.
The enhanced guidance reflects executive confidence in sustained performance from the immunology and neuroscience portfolios.
On a reported GAAP basis, quarterly net income totaled $695 million, translating to $0.39 per diluted share. This compares with $1.29 billion, or $0.72 per share, recorded in the prior-year quarter. The year-over-year GAAP contraction reflects expenses excluded from adjusted metrics.
Broader Context for ABBV Shareholders
The shares had experienced selling pressure leading into this announcement, trading down 13% year-to-date through Tuesday’s market close.
The premarket advance of 2.5% indicates investor appreciation for both the earnings beat and elevated guidance, though meaningful recovery remains ahead.
Skyrizi and Rinvoq have emerged as the undisputed growth catalysts within AbbVie’s portfolio, with their combined momentum more than compensating for Humira’s persistent decline.
Neuroscience has evolved into a more substantial revenue driver. The segment’s 26% growth trajectory demonstrates meaningful diversification beyond the flagship immunology franchise.
AbbVie’s adjusted earnings of $2.65 per share represented the second straight quarter of year-over-year expansion on this measure, with the prior-year comparable of $2.46 now clearly exceeded.
The company’s updated guidance corridor of $14.08–$14.28 in adjusted EPS establishes the full-year performance target that market participants will monitor throughout the remainder of 2026.
